1. Home
  2. |Insights
  3. |DoD Tightens Counterfeit Prevention Policy

DoD Tightens Counterfeit Prevention Policy

Client Alert | less than 1 min read | 05.02.13

On April 26, 2013, DoD issued an Instruction to establish policies to prevent the introduction of counterfeit material at any level of the DoD supply chain and to seek restitution for critical failures and damages caused by such material. DoD component heads are tasked with integrating the policy into contract requirements and procedures, procuring critical material only from suppliers that meet appropriate counterfeit avoidance criteria or applying additional risk management measures when such suppliers are not available, using sampling techniques and material testing for detection, and reporting all suspected or confirmed occurrences.

 

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights